Expression and clinical significance of SIRT2 in urothelial bladder cancer and its impact on cancer cell proliferation, invasion and migration

doi:10.16352/j.issn.1001-6325.2023.07.1090

Abstract

Abstract: Objective To investigate the expression and clinical significance of silent information regulator 2 (SIRT2) form tissue of urothelial bladder cancer(UBC) and the effects of down-regulation of SIRT2 on the proliferation, invasion and migration of bladder cancer cells. Methods The expression of SIRT2 protein was detected in 95 samples of urothelial bladder cancer tissues and 39 paracancerous tissues using the immunohistochemical EnVision method. Its relationship with clinicopathological parameters was analyzed. The expression of SIRT2 mRNA in bladder cancer cell lines was detected by RT-qPCR, and the expression levels of SIRT2 protein in bladder cancer cell lines, 12 pairs of fresh bladder cancer tissues were detected by Western blot. Lentiviral infection was used to stably downregulate the SIRT2 gene in bladder cancer cell line T24. CCK8 and cell colony assays were performed to detect changes in cell proliferation ability and Transwell assay to detect changes in cell invasion and migration activity. Results The positive expression rate of SIRT2 in urothelial bladder cancer tissues was 84%(80/95), which was higher than that in normal uroepithelial tissues (5%, 2/39) (P<0.05). The expression rate of SIRT2 was higher in the high-grade uroepithelial cancer group (95%, 38/40) than in the low-grade group (76%, 42/55) (P<0.05); The expression rate was higher in the muscle-infiltrated group (96%, 24/25) than in the non-muscle-infiltrated group (80%, 56/70) (P<0.05). Expression of SIRT2 protein was higher in fresh bladder cancer tissues than in normal tissues adjacent to the cancer. Expression of mRNA and protein of SIRT2 were also upregulated in bladder cancer cell lines. Knockdown of SIRT2 in T24 cells resulted in a significant decrease in cell activity of proliferation, invasion and migration (P<0.05). Conclusions SIRT2 is highly expressed in bladder uroepithelial carcinoma, and interfers with SIRT2 significantly and so inhibites bladder cancer cell proliferation, invasion and migration.

Key words: SIRT2, urothelial bladder cancer, immunohistochemistry, proliferation, invasion and migration

CLC Number:

R737.1

JIN Xiaoxia, LU Xiaoyun, LIU Yushan, LIANG Lina. Expression and clinical significance of SIRT2 in urothelial bladder cancer and its impact on cancer cell proliferation, invasion and migration[J]. Basic & Clinical Medicine, 2023, 43(7): 1090-1096.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.07.1090

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I7/1090

References

[1] Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review[J]. JAMA, 2020, 324:1980-1991.
[2] 曹毛毛, 陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志(电子版), 2021, 13:63-69.
[3] 白冰, 张海芳, 杨庆良, 等. 下调lncRNA RHPN1-AS1抑制人膀胱癌细胞系T24增殖和迁移[J]. 基础医学与临床, 2022, 42:940-944.
[4] W?troba M, Dudek I, Skoda M, et al. Sirtuins, epigenetics and longevity[J]. Ageing Res Rev, 2017, 40:11-19.
[5] Wang Y, Yang J, Hong T, et al. SIRT2: controversy and multiple roles in disease and physiology[J]. Ageing Res Rev, 2019, 55:100961. doi: 10.1016/j.arr.2019.100961.
[6] Liu HY, Liu YY, Yang F, et al. Acetylation of MORC2 by NAT10 regulates cell-cycle checkpoint control and resistance to DNA-damaging chemotherapy and radiotherapy in breast cancer[J]. Nucleic Acids Res, 2020, 48:3638-3656.
[7] Li C, Zhou Y, Kim JT, et al. Regulation of SIRT2 by Wnt/beta-catenin signaling pathway in colorectal cancer cells[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868:118966. doi: 10.1016/j.bbamcr.2021.118966.
[8] Zhu H, Hu Y, Zeng C, et al. The SIRT2-mediated deacetylation of AKR1C1 is required for suppressing its pro-metastasis function in non-small cell lung cancer[J]. Theranostics, 2020, 10:2188-2200.
[9] Aventaggiato M, Vernucci E, Barreca F, et al. Sirtuins’ control of autophagy and mitophagy in cancer[J]. Pharmacol Ther, 2021, 221:107748. doi: 10.1016/j.pharmthera.2020.107748.
[10] Jin X, Wei Y, Xu F, et al. SIRT1 promotes formation of breast cancer through modulating Akt activity[J]. J Cancer, 2018, 9:2012-2023.
[11] Liu CW, Lin YC, Hung CM, et al. CHM-1, a novel microtubule-destabilizing agent exhibits antitumor activity via inducing the expression of SIRT2 in human breast cancer cells[J]. Chem Biol Interact, 2018, 289:98-108.
[12] Kim HS, Vassilopoulos A, Wang RH, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity[J]. Cancer Cell, 2011, 20:487-499.

[1]	. Research on the molecular mechanism of total flavonoids of Hippophae inhibiting the proliferation of bladder cancer cells and promoting cells apoptosis through miR-144/PI3K/Akt signaling pathway [J]. Basic & Clinical Medicine, 2023, 43(7): 1122-1126.
[2]	TANG Yijun, WANG Wenlong, LI Jiangli, YANG Huan, SUN Jing. LncRNA RP11-686D22.10 is related with the survival of breast cancer patients, affects the proliferation, invasion of breast cancer cell lines [J]. Basic & Clinical Medicine, 2023, 43(7): 1023-1029.
[3]	. Down-regulation of BECN1 inhibits the proliferation, invasion and migration of human leukemia cell line THP-1 [J]. Basic & Clinical Medicine, 2023, 43(7): 1104-1109.
[4]	SU Jingyu, ZHANG Zhenxi, DU Wenjing. Effect of TPX2 expression on prognosis of pancreatic carcinoma [J]. Basic & Clinical Medicine, 2023, 43(6): 875-881.
[5]	HOU Mengjie, ZHAO Na, HUANG Fuqiang, WANG Yanan, LIU Fangming. Apolipoprotein E negatively regulates Golgi membrane protein 73 to inhibit the proliferation of mouse liver cancer cell lines [J]. Basic & Clinical Medicine, 2023, 43(5): 762-770.
[6]	LIU Yue, CAO Yang, GU Weiying, SHANG Limei, LIU Yan. Decitabine combined with arsenic trioxide inhibits proliferation and promotes apoptosis of acute myeloid leukemia cell lines [J]. Basic & Clinical Medicine, 2023, 43(4): 608-614.
[7]	WANG Fangfang, CAO Huiyuan, WANG Jing, WANG Ning, HUANG Guoliang. Up-regulation of miR-200c-5p inhibits proliferation of human colorectal cancer cell line SW480 [J]. Basic & Clinical Medicine, 2023, 43(2): 241-245.
[8]	YANG Liangquan, YU Miao, JIANG Qian, ZHANG Minghui, YANG Haisong. miR-504 regulates proteasome activator and inhibits the proliferation and migration of breast cancer cell line MCF-7 [J]. Basic & Clinical Medicine, 2023, 43(1): 95-101.
[9]	HE Jing, LI Yan, WANG Yan-feng, BAO Hui. Up-expression of FABP4 promotes the proliferation and migration of endometrial cancer cell line HEC-1-A [J]. Basic & Clinical Medicine, 2022, 42(9): 1356-1361.
[10]	ZHANG Xiao-lei, LIU Jing, LI Chao-ping. Circ_0032821 is involved in sorafenib's inhibition of the proliferation, migration and invasion of breast cancer cell line T47D [J]. Basic & Clinical Medicine, 2022, 42(9): 1350-1354.
[11]	WANG Juan, ZHANG Xiao-yan, ZHU Ai-hua, YU Hong-bo, FAN Xin-dan, TANG Chun-hui, YAO Xiu-fang. High expression of Ku70 promotes proliferation of ovarian cancer cell lines and is associated with a poor prognosis for patients [J]. Basic & Clinical Medicine, 2022, 42(9): 1391-1399.
[12]	SHEN Yong-hua, WANG Jun-feng, CHENG Ze-xing, FENG Juan-juan. Esculin inhibits the proliferation of human nasopharyngeal carcinoma cell line HNE-3 [J]. Basic & Clinical Medicine, 2022, 42(8): 1237-1242.
[13]	XIE Si-an, CHEN Yi-yang, XU Jun-xuan, NING Ting-ting, ZHANG Nan, ZHU Sheng-tao, ZHANG Shu-tian. Effect of PTOV1 expression on prognosis of colorectal cancer patients [J]. Basic & Clinical Medicine, 2022, 42(8): 1176-1181.
[14]	JIANG Ning, GUO Jun, LIU Cheng, ZHOU Ju. Curcumol inhibits proliferation and promotes apoptosis of human osteosarcoma cell lines [J]. Basic & Clinical Medicine, 2022, 42(8): 1200-1205.
[15]	LIU Lei, LI Shi-bao, ZHANG Hao-liang. Lnc-SLC2A12-10:1 silencing inhibits the proliferation, migration and invasion of gastric cancer cell line AGS [J]. Basic & Clinical Medicine, 2022, 42(7): 1071-1076.